Sputnik V isn't Russia's only homegrown COVID-19 vaccine. EpiVacCorona, first authorized in October 2020, has begun to emerge from the shadow of Sputnik V, bringing along controversy. Developed by VECTOR, the famed State Research Center of Virology and Biotechnology that once studied bioweapons and now is one of two global repositories of the eradicated smallpox virus, the vaccine is key to the country's plans to combat the pandemic. Russia began to offer it to small numbers of people last year and aims for a bigger national campaign. But only in late March did VECTOR publish any clinical data on EpiVacCorona, which consists mainly of multiple protein bits, or peptides, from the pandemic coronavirus, and there's still no evidence that the vaccine actually protects people from COVID-19. Moreover, participants in early trials of the vaccine say they have tested themselves for the antibodies the vaccine is meant to produce and they find none.

Sputnik V不是俄罗斯唯一的本土COVID-19疫苗。EpiVacCorona于2020年10月首次获得授权，已从人造卫星V的阴影中脱颖而出，引发了争议。该疫苗由著名的国家病毒学和生物技术研究中心VECTOR开发，该中心曾经研究过生物武器，现在已成为全球根除天花病毒的两个储存库之一，是该国抗击大流行计划的关键。去年，俄罗斯开始向少数人提供它，并计划进行更大范围的全国运动。但是直到三月下旬，VECTOR才在EpiVacCorona上发布任何临床数据，该数据主要由大流行性冠状病毒中的多个蛋白质片段或肽组成，并且仍然没有证据表明该疫苗实际上可以保护人们免受COVID-19侵害。而且，